A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Name: A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Creator: Vivli
Published: 2025-02-10 13:52:10
License: 暂无描述

DataCite Commons2025-02-10 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00009948/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.

提供机构：

Vivli

创建时间：

2024-04-03